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The cytoskeleton is one of the most mobile and complex cell structures. It is involved
in cellular transport, cell division, cell shape formation and adaptation in response
to extra- and intracellular stimuli, endo- and exocytosis, migration, and invasion.
These processes are crucial for normal cellular physiology and are affected in several
pathological processes, including neurodegenerative diseases, and cancer. Some
proteins, participating in clathrin-mediated endocytosis (CME), play an important role in
actin cytoskeleton reorganization, and formation of invadopodia in cancer cells and are
also deregulated in neurodegenerative disorders. However, there is still limited information
about the factors contributing to the regulation of their expression. MicroRNAs are
potent negative regulators of gene expression mediating crosstalk between different
cellular pathways in cellular homeostasis and stress responses. These molecules
regulate numerous genes involved in neuronal differentiation, plasticity, and degeneration.
Growing evidence suggests the role of microRNAs in the regulation of endocytosis,
cell motility, and invasiveness. By modulating the levels of such microRNAs, it may
be possible to interfere with CME or other processes to normalize their function. In
malignancy, the role of microRNAs is undoubtful, and therefore changing their levels
can attenuate the carcinogenic process. Here we review the current advances in our
understanding of microRNAs regulating actin cytoskeleton dynamics, CME and cell
motility with a special focus on neurodegenerative diseases, and cancer. We investigate
whether current literature provides an evidence that microRNA-mediated regulation of
essential cellular processes, such as CME and cell motility, is conserved in neurons,
and cancer cells. We argue that more research effort should be addressed to study
the neuron-specific functions on microRNAs. Disease-associated microRNAs affecting
essential cellular processes deserve special attention both from the view of fundamental
science and as future neurorestorative or anti-cancer therapies.
Keywords: microRNA, clathrin-mediated endocytosis (CME), neurodegenerative diseases, post-transcriptional
regulation, cancer, actin cytoskeleton, cell motility
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INTRODUCTION
Since the discovery of microRNA in 1993 (1), these 18–25
nt non-coding molecules have been recognized as important
post-transcriptional regulators of physiological and pathological
processes in different tissues and organs. MicroRNA biogenesis
is mediated by ribonucleases Drosha and Dicer in complex with
several regulatory proteins controlling specificity and activity
of these enzymes [reviewed in Bartel (2)] and is affected by
multiple signal transduction and stress response pathways (3–
8). Conversely, microRNAs mediate crosstalk between different
cellular pathways forming large-scale regulatory networks that
regulate cellular homeostasis and stress responses (2, 8–10).
Therefore, it is not surprising that microRNAs are implicated
in multiple pathological conditions. Indeed, microRNA levels
change in aging, cancer, and neurodegenerative diseases
[reviewed in Emde and Hornstein (5), Eacker et al. (11), Juzwik
et al. (12), and Konovalova et al. (13)]. The relative ease of
detection prompted research to exploit the possibility of using
microRNAs as biomarkers in multiple diseases and conditions.
The overwhelming majority of current clinical trials related to
microRNAs are investigating the possibility to use circulating and
exosomal microRNAs for early disease diagnosis (14–17). The
application of microRNAs as therapeutic molecules has proven
to be more challenging, but, nevertheless, a promising approach,
and indeed modulation of particular microRNAs has been
suggested for the therapy of cancers [reviewed in Hosseinahli et
al. (18) and Hanna et al. (19)] and neurodegenerative diseases
[reviewed in Sonntag (20), Junn and Mouradian (21), Sonntag
et al. (22), and Wen (23)].
To date, the role of microRNAs in the development and
disorders of the nervous system is investigated intensively (11).
MicroRNAs are known to influence numerous genes involved
in neuronal differentiation, plasticity and degeneration. For
instance, in Alzheimer’s disease (AD) several microRNAs can
target key genes involved in the production of amyloid-beta
(Aβ), inflammation and defects of neurotransmission: miR-
124 targets Aβ-cleaving enzyme 1 BACE1 thus preventing
Aβ formation, while downregulation of miR-15a promotes tau
hyperphosphorylation (24, 25). MicroRNAs and their biogenesis
machinery are also important disease-associated factors in
Parkinson’s disease (PD) (26, 27). Studies on post-mortem laser-
microdissected dopaminergic neurons demonstrate a reduction
of DICER1 gene expression in PD patients (28). Dicer is essential
for the function and survival of adult dopaminergic neurons
and pharmacological stimulation of microRNA biogenesis
pathway promotes dopaminergic neuron survival and protects
them from cellular stress (29). The level of Dicer expression
correlates with the severity of PD-related symptoms in mice,
and several microRNAs have been shown to target mRNA of
α-synuclein—a protein whose accumulation, aggregation and
spread can disrupt neurotransmission and neuronal metabolism
compromising neuronal functions already at the early PD
stages (26, 30, 31). Mutations in DICER1 gene and reduced
Dicer activity are associated with increased susceptibility to
stress, apoptosis, developmental abnormalities, aging, metabolic
disorders, disturbed immune system and neuronal functions,
and neurodegeneration (29, 32–48). Conversely, increased Dicer
levels and/or activity are mostly associated with increased cell
survival, but also tumorigenesis (6, 49–52).
The cytoskeleton is an essential cell structure consisting of
multiple well-regulated components. It is represented by the
three types of filaments: actin filaments, microtubules, and
intermediate filaments. These protein complexes form a tight
network functioning by assembly-disassembly, which requires
not only filaments themselves, but also the number of additional
factors. These factors are: nucleation promoting factors for
initial filament formation, capping factors preventing filament
growth, polymerization factors promoting fast and sustainable
filament growth, depolymerization factors for disassembling,
crosslinkers and stabilization factors for organizing and building
of more complex structures, and adapter proteins to facilitate the
multiprotein complex formation on every stage of the process
[reviewed in Hohmann and Dehghani (53)].
One of the most interesting aspects for research related
to cytoskeleton remodeling is its regulation or changes
in regulation during pathophysiological processes, such as
neurodegeneration or malignization. During the malignization
cell cycle, morphogenesis, and migration ability undergo
profound changes mediated by the expression level changes of
cytoskeletal additional factors. Transcription factors, nucleation
factors, polymerization factors, and certain Rho-GTPases are
known to be significantly dysregulated during both initial and
promoted carcinogenesis. Also, multiple proteins which are not
directly related to cytoskeleton reorganization machinery, but
take part in its remodeling as an event, such as transcription
factors directly involved in cytoskeleton machinery gene
expression or those involved in the epithelial–mesenchymal
transition (EMT) are investigated in the context of malignancy
(54, 55).
An appropriately organized neuronal cytoskeleton is
important for neurodevelopment and normal neuron
functioning. Dysregulation of either proper cytoskeletal
function or its network proteins (for example capping proteins
or those involved in tubulin post-transcriptional regulation)
are now the field of interest for new therapeutic targets for
neurodegenerative disorders [reviewed in Eira et al. (56)].
As such, the regulation of cytoskeleton dynamics and
functions is critical for cell survival. MicroRNAs are known to
affect the expression of cytoskeletal proteins both in normal
and disease conditions (57–62). We hypothesize that, given the
fundamental importance of cytoskeleton dynamics for essential
cellular processes, microRNAs regulating it would be involved
and affected in neurodegenerative diseases and carcinogenesis—
pathological processes which represent two opposite cellular
fates: either uncontrolled cell loss or abnormal cell proliferation,
migration, and survival. Reviewing the literature on microRNA-
dependent regulation of protein expression, we specifically aim
to evaluate this hypothesis and find published evidence on
whether microRNAs regulating cytoskeleton dynamics, as well as
tightly linked clathrin-mediated endocytosis (CME) and cellular
migration processes, are critical for both neurodegeneration, and
cancer. We suggest that such microRNAs will be very interesting
and important subject formore in-depth future studies both from
Frontiers in Neurology | www.frontiersin.org 2 November 2020 | Volume 11 | Article 549006
Gerasymchuk et al. MicroRNAs in Neurodegeneration and Cancer
the point of basic biology as well as possible therapeutic agents
and/or targets.
CLATHRIN-MEDIATED ENDOCYTOSIS
AND CYTOSKELETON DYNAMICS IN
NEURODEGENERATION AND CANCER
Among all types of cellular transport, CME is currently the
best characterized process that has been extensively studied
since its discovery in 1964 [reviewed in Maib et al. (63) and
Mettlen et al. (64)]. Numerous ligands, including transferrin and
epithelial growth factor (EGF), coupled to the corresponding
receptors are internalized via CME. The central event of CME
is the formation of a 50–100 nm clathrin-coated vesicle (CCV)
to transport molecular cargoes inside the cell (65). Generally,
the CCV is formed by five consecutive and partially overlapping
steps essential for CME [reviewed in McMahon and Boucrot
(66)]. The CCV is generated by binding of FCHO1/2 proteins to
phosphatidylinositol-4,5-bisphosphate-rich zones at the plasma
membrane followed by the formation of the FCHO1/2-EPS15-
EPS15R-intersectins complex to recruit AP2 and clathrin for
cargo selection and vesicle coating. GTPase dynamin then cuts
the CCV from the inner surface of the plasma membrane. When
molecular cargo has been delivered, the vesicle is disassembled
by ATPase HSC70 recruited by auxilin or cyclin G-associated
kinase (GAK). After delivery of molecular cargo and uncoating,
the vesicles can be assembled again from free components for the
next round of endocytosis.
The complexity of this process can be partially reflected
by the quantity of proteins participating at different steps of
CCV formation: to date, nearly 60 distinct proteins are known
to be involved in CME in yeasts, with 85% of those being
homologous to mammalian endocytic proteins (67). Additional
proteins can be recruited bymain participants, primarily, scaffold
and adaptor proteins, such as AP2 and intersectins, at different
stages. Altogether, while the main molecular events in CME have
been discovered, the detailed mechanisms regulating it are not
fully understood.
Being a vital process for cell life and development,
CME is tightly linked to multiple cellular pathways and
events. For many CME proteins, close association with
remodeling and regulation of the cytoskeleton has been
demonstrated. By using its DH-domain, a long isoform
of mammalian intersectins, adaptor/scaffold protein family
participating at the nucleation step of CCV formation interact
with guanine-exchange factor Cdc42 regulating its activity in the
polymerization of actin cytoskeleton via activation of N-WASP
and subsequent formation of filopodia—actin-rich protrusions
on the cell surface [reviewed in Herrero-Garcia and O’Bryan
(68)]. Recent reports showed the involvement of ITSNs in the
formation of mammalian oocytes through the Cdc42 pathway,
further confirming their role in the processes of growth and
development (69, 70). Additionally to the binding of Cdc42,
ITSN1 has been shown to colocalize and physically interact
with N-WASP and another cytoskeletal protein, WIP, further
promoting filopodia formation (71, 72). Another study reveals
the role of ITSN1-L in the actin-dependent dispersal of the
Golgi ribbon by interacting with GCC88, the Golgi ribbon
modulator (73). Almeida-Souza et al. (74) identified FCHSD2
as the major activator of actin remodeling in CME after
recruitment to endocytic pits by ITSN1 via unusual SH3-
SH3 interaction. The endocytic protein Numb which is also
involved in neural differentiation interacts with Rac and Cdc42
to induce reorganization of actin cytoskeleton and promote
cell migration (75). MARK, a microtubule-associated kinase,
which post-translationally phosphorylates several microtubule-
associated proteins including Tau, is colocalized and copurified
with AP2 complex and clathrin, explaining its influence on
CCV trafficking (76). Moreover, AP2 controls acetylation of
microtubules at clathrin-coated pits via interactions with α-
tubulin acetyltransferase αTAT1 thus having impact on the
motility of migrating cells (77). Dynamin 2 GTPase, which
cuts the CCV from the plasma membrane can enhance cell
motility, particularly in cancers, through direct interactions
with α-actinin 4 (78) and podocalyxin (79). In myogenesis,
dynamin 2 promotes the organization of actin filaments in the
invadosome to drive membrane fusion by direct interaction with
Tks5, a critical invadosome scaffold protein (80). The role of
dynamin as a unique multifilament actin-binding protein was
demonstrated in the recently discoveredmechanism of dynamin-
driven regulation of actin cytoskeleton. This mechanism is
based on the ability of dynamin to form an actin-bundling
helix with subsequent disassembly facilitating Arp2/3-mediated
branched actin polymerization. Dynamin assembly/disassembly
cycles promoted continuous actin binding resulting in the
formation of mechanically stiff super-bundles of actin (81).
Defects in endocytic machinery are often associated with
various disorders and can even be lethal. In neurons, CME
is an essential process for the delivery and replenishment of
synaptic vesicles carrying neurotransmitters to convert electric
stimuli to chemical signals (82–84). Neurodegenerative disorders
are linked to abnormalities in CME by mutations in endocytic
genes, inappropriate regulation and defective proteins that can
abolish uptake of molecular cargoes. In neurons, synaptic vesicle
endocytosis is mainly mediated through CME. Mutations in
auxilin gene, DNAJC6, an important brain-specific protein in
CCV uncoating, are associated with juvenile/early onset of
PD and development of epilepsy and intellectual disability in
addition to typical PD symptoms (85). In Drosophila models,
downregulation of auxilin leads to the progressive dopaminergic
neuronal loss and motor disabilities (86). Phosphorylation of
auxilin by LRRK2 results in the accumulation of oxidized
dopamine and overexpression of α-synuclein, one of the main
pathological proteins in PD development (87). Connor-Robson
et al. (88) demonstrated that the G2019S mutation in the LKKR2
gene in iPSC-derived dopaminergic neurons led to significant
deregulation of CME in synaptic vesicles by decreasing levels of
endophilin I-III, dynamin 2, and various RAB proteins resulting
in a functional impairment of the process. These data provide
more evidence of LRRK2-associated disruption of endocytosis
in PD development. Mutations in heterotetrameric adaptor
complex AP2, which recruits clathrin to the forming pit (89),
can lead to the development of various neurodevelopmental
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and other somatic disorders. As has been shown by Helbig
et al. (90), mutations in the µ-subunit-encoding AP2M1
gene impaired conformational activation and thermodynamic
entropy of AP2 complex resulting in the impairment of
CME and eventually contributing to the developmental and
epileptic encephalopathies.
Another adaptor/scaffold protein, intersectin 1 (ITSN1) has
been shown to be deregulated in AD and Down syndrome
(DS) patients, as well as in several cancers. In humans, the
ITSN1 gene is located on chromosome 21 and is overexpressed
in DS (91). Interestingly, in aged DS patients, levels of ITSN1
are decreased compared to the younger ones. Furthermore, DS
patients with concurrent AD diagnosis are characterized by
reduced levels of ITSN1 compared to DS-only cases. Mouse
models overexpressing the short isoform of ITSN1, ITSN1-
S, have reduced locomotor activity and abnormal behavioral
phenotype associated with the disruption of neuronal functions
due to interference with CME and other signaling pathways
(92). ITSN1-S deficiency in acute lung injury contributes to
endothelial barrier dysfunction and pulmonary edema (93),
whereas in lung cancer it induces ubiquitination of Eps8
oncoprotein leading to the impairment of Rac activation and
subsequent decrease of cancer cell migration and metastasis
(94). In Huntington’s disease, ITSN1 activates c-Jun-NH(2)-
terminal kinase (JNK)-MAPK pathway resulting in the increase
of aggregate formation by mutant huntingtin (95). Levels
of the neuron-specific long isoform of ITSN1, ITSN1-L,
are increased in refractory epilepsy patients and rat models
(96). Overexpression of ITSN1 leads to anchorage-independent
growth and tumorigenesis in neuroblastoma (97, 98) and
proliferation of glioblastoma cells through Raf/MEK/ERK
pathway activation (99), demonstrating an essential role of ITSN1
in the development of malignancy and tumor progression.
PICALM protein (also known as CALM), which binds the
heavy chain of clathrin and thus is involved in clathrin-coated
pit assembly (100), plays a role in the development of AD by
interacting with tau and mediating endocytosis of α-amyloid
protein (APP). In a murine tauopathy model with PICALM
haploinsufficiency, Ando et al. (101) demonstrated aggravation
of tau pathologies and tau-mediated neurodegeneration, whereas
in another study, PICALM overexpression resulted in faster
internalization of APP by CME and eventual enhancement of Aβ
production (102).
As a complex and multilayered process, CME undergoes
regulation at all steps of the formation of CCV by numerous
regulatory molecules and mechanisms. For instance,
agonist-activated G protein-coupled receptors (GPCRs)
are post-translationally phosphorylated and ubiquitinilated
leading to the recognition by adaptor proteins β-arrestins and
epsin1 and targeting to CCVs (103, 104). The AP2 complex,
which is activated by conformational changes in response to
phosphatidylinositol-4,5-bisphosphate (PIP2) and binding
of molecular cargoes at multiple sites (105), is allosterically
regulated by interactions with other adaptor/scaffold proteins
involved in CME (106, 107). Binding of AP2 to sorting signals
is regulated and enhanced by phosphorylation of its µ2 subunit
by AKK (108). Dynamin, another key protein for CME, not




Non-coding RNAs, primarily microRNAs, constitute
another level of regulation of gene expression, mainly post-
transcriptionally. There is still limited information about
regulation of intracellular trafficking pathways by microRNAs;
however, recent years yielded more evidence of the microRNA-
associated regulation of endocytosis. The microRNA cluster
miR-17∼92 is known as oncomir-1 due to its potent oncogenic
function and overexpressed in many cancers. It is a polycistronic
cluster that encodes 7 microRNAs which mainly facilitate
cell proliferation, malignancy, and tumorigenesis (110–116),
although for some microRNAs from this cluster an opposite
effect has been shown (117, 118). Known targets of microRNAs
encoded by this cluster are largely regulators of cell cycle
progression and apoptosis. In addition to these known effects,
the role of this cluster in endocytosis has been demonstrated.
A member of miR-17∼92 cluster, miR-17 regulates endocytic
trafficking by targeting TBC1D2/Armus and low-density
lipoprotein receptor (LDLR) participating in LDL trafficking.
According to Serva et al. (119) miR-17 directly targets 3′UTRs of
both genes and downregulates their expression. Consequently,
this leads to the reduction of mitotic cell numbers and inhibition
of cell proliferation. By regulating endocytic trafficking, miR-17
seed family potentially influences such processes as cell adhesion
that, in turn, might cooperate with other functions of miR-17 in
health and disease (119).
In gastrointestinal cancers like gastric, colon and liver cancers,
microRNAs can regulate not only known cancer-related signaling
pathways but also some other processes such as axon guidance,
neurotrophin/nerve growth factor signaling, and endocytosis.
Zhang et al. (120) confirmed regulation of EGF receptor
(EGFR) endocytosis by miR-17 and miR-145, predicted to target
endocytosis. While miR-17 promoted, miR-145 inhibited the
internalization of EGFR upon EGF binding to the plasma
membrane in human colon cancer cells SW1116. Blocking of
EGFR endocytosis by miR-145 resulted in prolonged EGFR
membrane signaling and altered responsiveness of colon cancer
cells to EGFR-targeting drugs (120).
Another microRNA, miR-199, gained particular interest
because of its origin from the introns of dynamin (DNM) genes.
DNM genes encode the conserved miR-199a and miR-199b
family of miRNAs within their intronic sequences. Sense strands
of the DNM genes are transcribed and translated to produce
DNM proteins that are involved in endosome trafficking. miR-
199a-5p is transcribed in the nucleus from the antisense strand of
introns in the DNM2 and DNM3 genes. miR-199a and miR-199b
regulate endocytic transport by downregulating the expression
of such endocytic genes as clathrin heavy chain (CLTC), Rab5A,
LDLR, and caveolin-1 (Cav-1) leading to the inhibition receptor-
mediated endocytosis in human cell lines Huh7 and HeLa
(121). Moreover, DNM2 gene derived miR-199 play roles in
Frontiers in Neurology | www.frontiersin.org 4 November 2020 | Volume 11 | Article 549006
Gerasymchuk et al. MicroRNAs in Neurodegeneration and Cancer
ovarian cancer metastasis by the regulation of hypoxia induced
factors HIF1 and HIF2. DNM2 levels are reduced in hypoxia
due to HIFs that have several binding sites in the DNM2
promotor region. In epithelial ovarian cancer cells, HIF1α and
HIF2α are reciprocally regulated by DNM2. Moreover, miR-199
encoded by the antisense strand of DNM2, decreased HIF1α
and HIF2α expression leading to the reduction of cell migration
and invasion, thus establishing the connection between hypoxia
and endocytosis in ovarian cancer (122). In addition to miR-
199, two other microRNAs, miR-3120-5p and miR-214-3p, are
synthesized from sense and antisense strands of the DNM3
intron, respectively. Moreover, miR-3120 was demonstrated to
be located in neuronal cell bodies and regulate genes of other
CME-associated proteins, Hsc70 and auxilin, inhibiting CCV
uncoating (123).
ITSNs are involved in multiple processes in the cell. Among
them, is regulation of expression of the epithelial sodium channel
(ENaC) in the kidney nephron, a major determinant of sodium
(Na+) and water balance. Aldosterone hormone has been shown
to regulate microRNA expression of the mmu-miR-23-24-27
cluster in the cortical collecting duct (CCD) in the kidney
nephron both in vitro and in vivo. In the absence of aldosterone
stimulation upregulation of these microRNAs increased Na+
transport. ITSN2 has been confirmed as a direct target for miR-
27 from the mmu-miR-23-24-27 cluster. Moreover, aldosterone
was also able to decrease ITSN2 alongside miR-27. Since ENaC
can interact with clathrin with effect on endocytic retrieval from
the apical membrane and ITSN2 is involved in facilitation of
this event, decrease of ITSN2 levels may delay ENaC removal
from the apical surface of CCD (124). Regulation of ITSN1
by microRNAs has also been demonstrated. Lin et al. (125)
studied the role of miR-194 in kidneys where it mediates K+
intake by the ROMK channel. High K+ intake increased mmu-
miR-194 levels which in turn led to the increased activity of
ROMK channels with the decrease of ITSN1 expression. ITSN1
has been confirmed as a direct target of miR-194 in luciferase
assays and Western blot analysis. The authors concluded that
miR-194 can regulate ROMK channel activity by modulating
ITSN1 levels and possibly enhancing ITSN1/WNK-dependent
endocytosis (125).
Perfluorooctanoic acid (PFOA) is used in a vast amount
of industrial and consumer products and there are concerns
that it may result in testicular toxicity. According to the
study performed by Lu et al. (126), PFOA exposure changed
levels of the proteins that were involved in endocytosis
(and, narrower, receptor-mediated endocytosis) and blood-
testis barrier, namely, ITSN1, serine protease inhibitor A3K
(Serpina3k), and apolipoprotein a1 (APOA1). In addition
to proteins, several microRNAs were also downregulated.
Analysis of potential regulatory pairs between deregulated
genes and microRNAs after PFOA exposure revealed a set
of potential miR-gene pairs, among which a pair of miR-
133b-3p/CTLA (clathrin light chain A) was confirmed in the
luciferase assay. This suggests a role of miR-133b-3p in the




MicroRNAs play an important role in normal cellular
homeostasis via regulating multiple pathways involved in
cell growth, proliferation and migration. These cellular activities
are dysregulated in cancer cells, leading to uncontrolled tumor
growth and metastasis formation. Multiple microRNAs were
shown to be significantly up- or downregulated in different
cancers. Frequently, their targets are involved in pathways
affecting transcription factor repression or activation, chromatin
remodeling machinery, cytoskeleton and adhesion molecules,
cell cycle regulators, and metabolic genes, for example, involved
in glucose metabolism. OnemicroRNA can affect one or multiple
targets within one pathway, as well as affect multiple pathways,
which makes these molecules promising potential biomarkers
and drug targets for tumor treatment and preventing cancer cell
migration. The effect of certain microRNA action may differ
from cell type to cell type due to different transcriptomes and
hence different interactomes, although certain microRNAs may
have a constant effect on multiple cell types. In this section, we
discuss recent papers demonstrating microRNAs’ contribution
to neural tumorigenesis with the main focus on glioma as the
most aggressive malignancy. Multiple microRNAs regulate cell
motility, proliferation and division events targeting different
genes, including those involved in cytoskeleton reorganization.
For example, members of the microRNA-200 family are involved
in regulation of cellular growth and migration via targeting
filamin, a protein important for actin filament organization, and
RhoGDIA, required for cytoskeleton dynamics (see Table 1)
(162, 163). If certain microRNA is dysregulated in specific
tumor cells, the rate of dysregulation may be a helpful tool for
diagnosis. Certain microRNAs can be potential biomarkers for
tumor grade verification, and target identification is important
for understanding whether a particular microRNA promotes
uncontrolled tumor cell division, or helps to invade, or both,
which may help to specify an individual therapeutic strategy.
Recent studies show numerous microRNAs to be downregulated
in glioma and correlate with tumor grade. For example,
expression levels of miR-1254 were significantly lower in glioma
cell lines compared to those in normal human astrocytes, as
well as in glioma tissue samples in comparison with normal
brain tissue. Higher expression level was associated with higher
survival rate in patients with primary and recurrent glioma,
as well as in vitro, upregulated miR-1254 decreased glioma
cells invasive, migratory and proliferative potentials via direct
targeting of CSF-1, which is known to regulate macrophage
motility, migration and maturation (164, 165).
MicroRNAs can both directly affect transcription factors and
upstreammolecules in the same signaling pathway. Upregulation
of miR-129-5p in glioblastoma cell lines LN229 and A172 led to
significant reduction of cell proliferation and colony formation
ability, also wound closure potential of the cells overexpressing
mir-129-5p was lower compared to intact cells. ZFP36L1, an
early response gene, was identified as a downstream target
of miR-129-5p, promoting cell invasiveness, proliferation and
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TABLE 1 | Role of microRNA regulating some endocytic genes in neurodegeneration and cancer/invasion.
microRNA Role in endocytosis Role in neurodegeneration Role in cancer and invasion
miR-17 Regulation of TBC1D2/Armus and
LDLR participating in LDL trafficking
(119); promotion of EGFR
internalization in human colon cancer
cells SW1116 (120)
MiR-17 is overexpressed in peripheral
mononuclear blood cells (PMBC) from PD
patients (127), downregulation of miR-17
led to paraquat-induced dopaminergic
degradation (128); miR-17 responses to
formaldehyde treatment and modulates
EPHA4, GNPDA2 and TXNIP expression
in the brains of MGMT–/– mice involved in
amyloid deposition, neurotransmission,
and response to oxidative stress (129)
miR-17 inhibits HGF/ERBB3-NF-kB positive loop
suppressing post-operative metastasis of HCC (130);
miR-17 downregulated netrin 4 promoting migration and
invasion of breast cancer cells (131); miR-17 targets SIK1
leading to the proliferation and migration of human
colorectal cancer cells (132); overexpression of miR-17 in
human fibroblasts co-cultured with colon cancer cells
remarkably reduced invasion of cancer cells (133); miR-17
targets ETV1 in triple negative breast cancer suppressing
proliferation, migration, and tumor metastasis (134)
miR-145 Inhibition of EGFR internalization in
human colon cancer cells SW1116
(120)
miR-145-5p downregulated NR4A2
leading to neuronal cell death (135),
downregulation of miR-145 induces
astrogliosis after spinal cord injury (136),
miR-145 is differentially expressed in
multiple sclerosis (137)
miR-145 targets CDCA3 leading to the suppression of
proliferation, EMT, and metastasis of colorectal cancer
(138); in upper tract urothelial carcinoma, miR-145 targets
ARF6 repressing cell migration, and invasion (139);
miR-145 targets WNT2B leading to suppression of cervical
cancer progression and metastasis (140); miR-145 targets
NF-kB pathway inhibiting invasion and migration of
papillary thyroid carcinoma cells (141); miR-145 targets
TWIST leading to the inhibition of migration and invasion of
colorectal cancer cells (142)
miR-199 Downregulation of clathrin heavy
chain (CLTC), Rab5A, low-density
lipoprotein receptor (LDLR), and
caveolin-1 (Cav-1) expression leading
to the inhibition receptor-mediated
endocytosis in human cell lines Huh7
and HeLa (121)
Prenatal circulating miR-199 is
upregulated in plasma samples in
pregnant women with fetal Down
syndrome (143); in CSF of AD patients,
miR-199b-5p is expressed more often
comparing to other microRNAs (144)
Decrease of HIF1α and HIF2α expression levels leading to
the reduction of cell migration and invasion (122); miR-199
targets Snail resulting in inhibition of EMT and invasion of
hepatoma cells (145); miR-199 downregulated RGS17
resulting in suppression of proliferation, migration, and
invasion of hepatocellular carcinoma cells (146)
miR-3120 Downregulation of Hsc70 and auxilin,
inhibiting CCV uncoating (123)
No data (March 2020) No data (March 2020)
miR-27 Downregulation of ITSN2 resulting in
the delay of ENaC removal from CCD
in kidneys (124)
No data (March 2020) Overexpressed miR-27 promoted multiple myeloma cell
proliferation, cell migration, and invasion (147); miR-27b
targets Sp1 leading to the inhibition of growth and invasion
of NSCLC cells (148); miR-27 is overexpressed in invasive
adenocarcinomas with the linear increase of microRNA
level according to the stage (149); miR-27a targets tumor
suppressor MCPH1 in renal cancer (150); upregulation of
miR-27a promoted migration, invasion, and angiogenesis
of thyroid cancer cells (151)
miR-194 Regulation of ROMK channels activity




In ALS, miR-194 is downregulated (152);
in the prefrontal cortex of late-onset AD
patients, miR-194 is upregulated (153); in
the blood of AD patients, miR-194-5p is
significantly downregulated (144)
miR-194 suppresses high glucose-induced progression of
non-small cell lung cancer by targeting NFAT5 (154);
overexpression of miR-194 in nasopharyngeal carcinoma
suppresses cell proliferation, migration, and invasion by
targeting MAP3K3 (155); in breast cancer, miR-194-5p
promotes cell proliferation, migration, and invasion by
targeting SOX17 (156); in prostate cancer, miR-194 is a
driver of cancer metastasis promoting migration, invasion,
and EMT (157)
miR-133 Decrease of CTLA levels after PFOA
exposure leading to the disturbance
of receptor-mediated endocytosis
(126)
miR-133 is overexpressed in serum of ALS
patients (158)
In lung adenocarcinoma metastasis cells, miR-133 acts as
a tumor suppressor targeting FLOT2 via Akt signaling
pathway (159); in gastric cancer, miR-133 downregulates
CDC42 expression, and PAK activation inhibiting cancer
cell proliferation and migration (160); in U87 glioma cell
lines, miR-133 targets FOXC1 suppressing tumor growth,
and invasion (161)
migration (166). In vitro, overexpressed miR-1471 showed less
proliferation activity compared to the control group, moreover,
ectopic expression of miR-1471 could inhibit glioma cell line
invasion ability. Such effects were caused by direct targeting
of metadherine, which has dual roles in metastasis seeding
and promoting chemoresistance in breast cancer (167, 168).
Interestingly, MTDH is required for RISC complex formation
and its optimal activity, which can affect miR-induced silencing
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by miR-1471, and it also interacts with spliceosome proteins
YTHDC1, Sam68, and T-STAR, thus playing an important role
in alternative splicing events (169, 170).
miR-940 was also significantly downregulated in glioma
samples and overexpression in cell lines U87 and LN229
dramatically decreased expression levels of mesenchymal
markers, such as N-cadherin, Vimentin, Fibronectin, α-SMA,
and MMP2. On the other hand, epithelial marker E-cadherin
was upregulated compared to the control group. Migration
and invasion rates of glioma cells overexpressing miR-940
were significantly reduced compared to control groups, and it
was shown that miR-940 influences these cell abilities through
the EMT pathway by targeting ZEB2—a transcription factor
activated by TGFβ (171). Also, miR-940 can induce G1/S phase
arrest and increase apoptosis rate via targeting MTHFD, an
enzyme participating in one-carbon metabolism of folate in
mitochondria, which makes miR-940 a promising biomarker
and therapeutic target for glioma (172, 173). Another zinc finger
protein, ZBTB20, was upregulated in GBM samples. It is involved
in glucose and lipid metabolism and is also associated with the
progression of hepatocellular carcinoma as an independent
marker (174–176). It was significantly upregulated in GBM cells
but overexpression of miR-758-5p resulted in decreasing ZBTB20
expression levels and inhibition of invasion, proliferation and
migration of GBM cells (177).
The most important features of invasive cells are their
ability to lose adhesion, anchorage-independent growth and
capacity to degrade extracellular matrix which helps to reach
not only adjusted tissues, but also distinct organs. Such activities
require a large number of different proteins involved in
cytoskeleton reorganization, matrix degradation and signaling,
thus multiple papers investigate microRNAs as regulators of
invasion-related genes.
Genome-wide analysis of potential miR-200 targets performed
by Bracken’s group revealed that this microRNA can regulate
invadopodia and focal adhesion through multiple signaling,
for example inhibiting Rho signaling either via its activators,
ARHGEF3 and NET1, and multiple downstream effectors,
and effectors of effectors. It may also affect the number of
transcription factors involved in invasion such as ZEB1, SUZ12,
STAT5B, E2F3, TCF12, CTNNB1, and several SMADs (178).
The fibulin glycoproteins family functions as regulators of
cell morphology, adhesion, proliferation and motility. Fibulin-
3 was shown to regulate matrix metaloproteinases (MMPs) and
tissue inhibitors of MMPs. It can either promote or repress
malignant behavior due to different cell context, but in glioma
cells it is upregulated, increasing invasion rates. miR-338-5p
directly targets its 3′UTR and serves as a tumor suppressor
in glioma (179). Moreover, miR-338-5p may regulate FOXD1,
which leads to suppression of MAPK-signaling in glioma cells
and therefore less proliferation and invasion activity (180). miR-
93-5p could repress invasion by direct targeting of MMP2, which
is essential for ECM digestion and subsequent migration of
tumor cells (181). Interestingly, miR-10b regulated the orchestra
of transcription factors such as HOXD10, PAX6, TP53, and
NOTCH1, repressing invasion-related genes RHOC, PLAUR,
MMP2, and CTNNB1, and decreasing the invasive potential of
mesenchymal type glioma cell line U87-2M1 (182). MicroRNA-
145 was significantly downregulated in glioma tissues, as
well as in U87, and U251 cell lines. ROCK1, its target, is
one of the key players of actin cytoskeleton reorganization,
which promotes tumor cell invasion through affecting the
RhoA/ROCK1 signaling pathway (183). Interestingly, certain
microRNAs may be potentially used as the differential markers
for glioma grade diagnostics due to the changes of their
expression level during tumor progression, making microRNA
profiling of different tumors at different stages a very promising
tool for further understanding of malignancy mechanisms (184).
COMMON microRNAs IN CANCER AND
NEURODEGENERATION
As discussed above, the processes of CME, invasiveness, and
cell motility are intrinsically linked by the cytoskeleton and its
dynamic reorganization. MicroRNAs regulating genes involved
in cytoskeleton dynamics can modulate cell invasiveness,
motility, and CME and thus also neuronal physiology and
survival. Since the general mechanism of CME is universal for
all cells and tissues it can be hypothesized that endocytic genes
may undergo similar regulation in neurons as they are regulated
in non-neuronal cells. While further studies addressing the role
of microRNAs in post-mitotic neurons are clearly necessary, can
we attempt to extrapolate the findings from cultured cell lines, if
particular microRNAs and their targets are expressed in neurons?
Starting from the hypothesis about the universal mechanism
of post-transcriptional regulation of the cytoskeleton and
CME proteins, we reviewed here the literature describing the
role of cytoskeleton- and endocytic-associated microRNAs
in neurodegeneration and cancer/invasion, aiming to find
possible common microRNAs. However, according to the
current literature, there is no significant overlap in microRNAs
in neurodegeneration and cancer. Some microRNAs associated
with endocytosis participate both in neurodegeneration and
tumorigenesis (Table 1). However, the same microRNA
molecules are reported to target different genes in different
cellular contexts. It is, therefore, important to be careful when
making profound conclusions about “universal” microRNAs
regulating all processes in the same manner in different
cell types, for example, when extrapolating findings from
cultured cells to post-mitotic neurons. On the other hand, the
absence of clear evidence about CME regulation in neurons
by microRNAs regulating endocytosis in non-neuronal cells
does not necessary imply the absence of the regulation itself.
Compared to immortalized cancer cells, neurons are technically
challenging to work with, as they are not dividing, difficult
to transfect and culture, and, accordingly, only a handful of
studies directly addresses microRNA functions in neuronal cells.
Moreover, post-transcriptional regulation of some isoforms
may be restricted to neurons or even particular types of
them complicating studies of gene regulation in neurons
even more. Multiple evidences demonstrate the presence of
neuron-specific transcripts as well as specific regulation of
widely expressed genes. A long isoform of human ITSN1
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gene, ITSN1-L, which is expressed primarily in neurons
carries unusually long 3′UTR of 11,561 nucleotides suggesting
neuronal-specific regulation of this transcript although no
data supports this hypothesis so far (185). Two isoforms with
different 3′UTRs of the major cytoskeletal protein β-actin
coexist in mouse neurons with much lower expression level,
but significantly higher translational efficiency of the transcript
with longer 3′UTR. Interestingly, the β-actin transcript with
longer 3′UTR harbors conservative target site of mmu-miR-34,
which upregulates β-actin expression (186). Brain-derived
neurotrophic factor (BDNF) critical for the development and
plasticity of neurons undergoes transcript-specific regulation
by miR-206 inhibiting only an isoform with long 3′UTR
without affecting a transcript with a shorter 3′UTR. Such
specific regulation led to the decrease of BDNF expression in
cell bodies and axons (187). Another example of transcript-
specific 3′UTR with distinct regulation is Nurr1 transcription
factor. Its long 3′UTR is targeted by miR-93, miR-204, and
miR-302d in rat mesencephalic neurons resulting in fine-tuning
of Nurr1 transcript-specific expression and possibly affecting
the development and survival of dopaminergic neurons (188).
Single nucleotide polymorphisms (SNPs) and short structural
variants (SSVs) may also affect microRNA binding sites and
mRNA expression. However, in contrast to long splice- and
transcript-specific variants of 3′UTRs the evidence of such
regulation is limited. Genetic variations of α-synuclein 3′UTR
were found in PD and Dementia with Lewy Bodies (DLB)
patients, however, no specific microRNAs binding these sites
were identified (189, 190).
Existence of tissue-specific transcripts can partially
explain difficulties in the understanding of microRNA-
driven regulation of a particular cellular pathway. Thus,
for any particular microRNA, the effort should be made to
identify the majority of its targets in different cell types, which
can be done by profiling mRNAs after overexpression or
inhibition of a particular microRNA. With current advances
in RNA sequencing it becomes increasingly possible. Only
when we have a more complete picture of the scope of
particular microRNA targets, we can make clear conclusions
about whether these are the same or different in different
cell types.
With this review of the current literature, we argue
that more research specifically focused on the role of
microRNAs regulating CME and cytoskeleton dynamics in
neurons is urgently needed. Currently, we can conclude
that at least some endocytic-associated microRNAs with
strictly proven roles in cancer and neurodegeneration
are worth paying more attention to as possible
therapeutic targets.
FUTURE PERSPECTIVES
Multiple studies discussed above indicate the important role
of microRNAs in regulation of CME and cell invasiveness.
Nevertheless, many publications rely on studies in cultured
cells, which is especially problematic when such results are
extrapolated to post-mitotic neurons. The results obtained
using reporter constructs to demonstrate the targeting of a
particular gene with a selected microRNA must be confirmed
by demonstrating its effect on an endogenous target. Frequently,
non-physiological levels of synthetic microRNA mimics and/or
inhibitors are transfected to cells, even though their unspecific
effects are well-known (191). Further, as one microRNA is
capable of regulating multiple targets, the effects of microRNA
mimics and inhibitors will affect all targets of this particular
microRNA, and therefore, the results of such experiments must
be interpreted with caution. This problem can be overcome by
the use of specific target protectors, disrupting the interaction
of particular microRNA with its selected mRNA target (192).
When uncovering microRNA regulatory networks and targets,
we must aim at demonstrating that endogenous microRNA can
regulate the endogenous target mRNA in the selected cell type
of interest resulting in measurable functional effects. We should
also bear in mind species-specific differences in microRNAs
as well as in 3′UTR sequences and, therefore, in microRNA
regulatory networks, which has already been demonstrated at
least for some genes (193, 194). Also, the further advance of
methods to study microRNA/mRNA interactions (195) as well
as bioinformatic algorithms for microRNA target prediction
(196) will improve our understanding of microRNA regulatory
networks in different cellular processes. Clearly, more careful
and controlled research is needed to address the importance and
the extent of microRNA-mediated regulation of CME and cell
motility. This will hopefully lead to discovery of new targets
and the development of microRNA-based therapies for cancer
and neurodegeneration.
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